EP Patent

EP0261429A1 — Penetration enhancement systems and the preparation thereof

Assigned to Warner Lambert Co LLC · Expires 1988-03-30 · 38y expired

What this patent protects

The application describes a transmembranally administrable composition comprising; (a) about 0.2% to about 5% of bioaffecting agent, (b) about 1% to about 20% of fatty component, and (c) about 80% to about 99% of a secondary component. as well at its preparation.

USPTO Abstract

The application describes a transmembranally administrable composition comprising; (a) about 0.2% to about 5% of bioaffecting agent, (b) about 1% to about 20% of fatty component, and (c) about 80% to about 99% of a secondary component. as well at its preparation.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

Patent Metadata

Patent number: EP0261429A1
Jurisdiction: EP
Classification: —
Expires: 1988-03-30
Drug substance claim: No
Drug product claim: No
Assignee: Warner Lambert Co LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.